1. Scrip
  2. >>Business

S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line

 
• By Jessica Merrill

Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.

Thumbs up and down
Biopharma's S&E highs and lows • Source: Alamy

Regeneron Pharmaceuticals, Inc. generated $262m in the first quarter from the sale of its monoclonal antibody cocktail REGEN-COV (casirivimab/imdevimab) against COVID-19, driving a 38% increase in the company's revenues to $2.53bn. Excluding REGEN-COV, company revenues grew 20%, with strong growth of Dupixent (dupilumab) and Eylea (aflibercept) contributing to the gain.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.